Cargando…
PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429252/ http://dx.doi.org/10.1097/01.HS9.0000850960.38950.59 |
| _version_ | 1784779382345170944 |
|---|---|
| author | Fonseca, R. Kuroda, J. Ishida, T. Popat, R. Huang, J. S. Yver, A. Vandendries, E. Elmeliegy, M. Ma, W. D. Sborov, D. W. |
| author_facet | Fonseca, R. Kuroda, J. Ishida, T. Popat, R. Huang, J. S. Yver, A. Vandendries, E. Elmeliegy, M. Ma, W. D. Sborov, D. W. |
| author_sort | Fonseca, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429252 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292522022-08-31 PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Fonseca, R. Kuroda, J. Ishida, T. Popat, R. Huang, J. S. Yver, A. Vandendries, E. Elmeliegy, M. Ma, W. D. Sborov, D. W. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429252/ http://dx.doi.org/10.1097/01.HS9.0000850960.38950.59 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Fonseca, R. Kuroda, J. Ishida, T. Popat, R. Huang, J. S. Yver, A. Vandendries, E. Elmeliegy, M. Ma, W. D. Sborov, D. W. PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2032: magnetismm-9: an open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429252/ http://dx.doi.org/10.1097/01.HS9.0000850960.38950.59 |
| work_keys_str_mv | AT fonsecar pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT kurodaj pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT ishidat pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT popatr pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT huangjs pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT yvera pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT vandendriese pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT elmeliegym pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT mawd pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma AT sborovdw pb2032magnetismm9anopenlabelmulticenternonrandomizedphase12studyofelranatamabinpatientswithrelapsedrefractorymultiplemyeloma |